Levosulpiride

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Levosulpiride
Levosulpiride.svg
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C15H23N3O4S
Molar mass 341.43 g·mol−1
 NoYesY (what is this?)  (verify)

Levosulpiride is a substituted benzamide antipsychotic,[1] reported to be a selective antagonist of dopamine D2 receptor activity[2] on both central and peripheral levels. It is an atypical neuroleptic and a prokinetic agent.[2] Levosulpiride is also claimed to have mood elevating properties.

Chemically, it is the (S)-(−)-enantiomer of sulpiride.

Uses[edit]

Levosulpiride is used in the treatment of:

Levosulpiride is not currently licensed for treatment of premature ejaculation in the UK or other European countries.[3]

Side effect[edit]

Side effects include amenorrhea, gynecomastia, galactorrhea, changes in libido, and neuroleptic malignant syndrome.[4] In the U.S., as of 2013 only one case of adverse reaction to Levosulpiride had been recorded on the FDA Adverse Event Reporting System Database.[5] A case of rapid onset resistant dystonia caused by low dose levosulpiride was reported in India.[6]

Mechanism of action[edit]

In contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.[7]

Pharmacodynamics[edit]

Sulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.[7]

References[edit]

  1. ^ Generon. "Levosulpiride - S-(-)-Sulpiride - >98% Generon". www.generon.co.uk. Retrieved 2016-08-31. 
  2. ^ a b http://www.stratech.co.uk/. "Levosulpiride | Stratech Scientific Ltd". www.stratech.co.uk. Retrieved 2016-08-31. 
  3. ^ Poluzzi, Elisabetta; Raschi, Emanuel; Koci, Ariola; Moretti, Ugo; Spina, Edoardo; Behr, Elijah R.; Sturkenboom, Miriam; Ponti, Fabrizio De (2013-04-04). "Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database". Drug Safety. 36 (6): 467–479. doi:10.1007/s40264-013-0032-z. ISSN 0114-5916. PMC 3664739Freely accessible. PMID 23553446. 
  4. ^ http://www.drugsupdate.com/generic/view/860
  5. ^ Poluzzi, Elisabetta; Raschi, Emanuel; Koci, Ariola; Moretti, Ugo; Spina, Edoardo; Behr, Elijah R.; Sturkenboom, Miriam; Ponti, Fabrizio De (2013-04-04). "Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database". Drug Safety. 36 (6): 467–479. doi:10.1007/s40264-013-0032-z. ISSN 0114-5916. PMC 3664739Freely accessible. PMID 23553446. 
  6. ^ "Rapid onset resistant dystonia with low dose of Levosulpiride". 2016-08-24. 
  7. ^ a b "Sulpiride". Drugbank.ca. DB00391.